

CHOP Down-Regulates cFLIP_L Expression by Promoting Ubiquitin/Proteasome-Mediated cFLIP_L Degradation

Hyo-Jeong Noh,¹ Sung-Jun Lee,¹ Eon-Gi Sung,¹ In-Hwan Song,¹ Joo-Young Kim,¹ Chang-Hoon Woo,² Taeg Kyu Kwon,³ and Tae-Jin Lee^{1*}

¹Department of Anatomy, College of Medicine, Yeungnam University, 317-1 Daemyung-Dong Nam-Gu, Daegu 705-717, Korea

²Department of Pharmacology, College of Medicine, Yeungnam University, 317-1 Daemyung-Dong Nam-Gu, Daegu 705-717, Korea

³Department of Immunology, School of Medicine, Keimyung University, 2800 Dalgubeoldaero, Dalseo-Gu, Daegu 704-701, Korea

ABSTRACT

The transcription factor CHOP/GADD153 is induced during the unfolded protein response and is related to the induction of ER stress-mediated apoptosis. However, how CHOP is organized between the pro-survival and pro-apoptotic roles of ER stress remains largely undefined. In this study, we identified the apoptosis regulating protein suppressed by CHOP. We found that treatment of Caki cells with CHOP-inducing drugs including withaferin A, thapsigargin, brefeldin A, and silybin led to a strong reduction in cFLIP_L protein levels together with a concomitant increase in the CHOP protein. Interestingly, Wit A down-regulated cFLIP_L expression via both suppressing mRNA transcription and increasing cFLIP_L protein instability. We also found that forced expression of CHOP dose-dependently led to a decrease of cFLIP_L protein expression but did not alter cFLIP_L mRNA levels. Additionally, we observed that siRNA-mediated CHOP silencing recovered the cFLIP_L expression decreased by CHOP-inducing agents in Caki cells. Finally, we showed that CHOP facilitates ubiquitin/proteasome-mediated cFLIP_L degradation, leading to down-regulation of cFLIP_L. Finally, cFLIP_L over-expression reduced cell death induced by treatment with brefeldin A, thapsigargin, and silybin. Taken together, our results provide novel evidence that cFLIP_L is a CHOP control target and that CHOP-induced down-regulation of cFLIP_L is due to activation of the ubiquitin/proteasome pathways. *J. Cell. Biochem.* 113: 3692–3700, 2012. © 2012 Wiley Periodicals, Inc.

KEY WORDS: CHOP; cFLIP_L; ER STRESS; UBIQUITIN/PROTEASOME

CFLIP_L is catalytically inactive homolog of caspase-8, which inhibits caspase-8 recruitment and processing at the DISC [Krueger et al., 2001]. cFLIP_L consists of the N-terminal death effector domains and a C-terminal caspase-like domain that does not possess enzymatic activity [Goltsev et al., 1997]. cFLIP_L is first processed to a truncated p43 form by caspase 8, which inhibits complete processing of caspase-8 to its active subunits. cFLIP_L over-expression protects against apoptosis mediated by the death receptors including FasL and TRAIL in several cancer cells in vitro [Irmeler et al., 1997; Shu et al., 1997; Medema and Borst, 1999]. cFLIP_L over-expression potently inhibits chemotherapeutic drug-induced cell death in solid tumor-derived cancer cell lines [Matta

et al., 2002; Longley et al., 2006]. These reports suggest that cFLIP_L is responsible for protecting against various anti-cancer drugs, inducing death receptor- or mitochondrial-mediated apoptosis. Previous reports have indicated that cFLIP protein levels are transcriptionally regulated through the nuclear factor- κ B or c-fos pathways [Micheau et al., 2001; Ichikawa et al., 2006; Zhang et al., 2007] or by ubiquitin/proteasome- and caspase-mediated degradation [Fukazawa et al., 2001; Lee et al., 2006; Palacios et al., 2006].

CHOP (CCAAT-binding homologous protein; GADD 153) was originally identified as a gene induced in response to genotoxic stress and growth arrest signals [Fornace et al., 1988]. CHOP is also been involved in the critical cellular response for the transcriptional

H.-J. Noh and S.-J. Lee contributed equally to this work.

Additional supporting information may be found in the online version of this article.

Grant sponsor: Korea Government (MEST); Grant number: 210-C-000162.

*Correspondence to: Tae-Jin Lee, Department of Anatomy, College of Medicine, Yeungnam University, 317-1 Daemyung-Dong Nam-Gu, Daegu 705-717, Korea. E-mail: tjlee@med.yu.ac.kr

Manuscript Received: 22 October 2011; Manuscript Accepted: 21 June 2012

Accepted manuscript online in Wiley Online Library (wileyonlinelibrary.com): 2 July 2012

DOI 10.1002/jcb.24242 • © 2012 Wiley Periodicals, Inc.

control of endoplasmic reticulum (ER) stress-mediated apoptosis. Upon nuclear translocation, CHOP up-regulates transcription of proapoptotic factors and down-regulates antiapoptotic genes [Wang et al., 1998; Zinszner et al., 1998]. For example, (i) CHOP up-regulates expression of carbonic anhydrase VI, which is predicted to increase proton concentration and decrease intracellular pH; (ii) CHOP increases expression of a homolog of Tenm/Odz that might function in signaling at compartment boundaries; (iii) CHOP induces a homolog of the actin-binding proteins, which is implicated in changes in the actin cytoskeleton during apoptosis; and (iv) CHOP leads to enhanced expression of Death Receptor 5 (DR5), which activates the TRAIL-mediated apoptotic pathway. In contrast, CHOP overexpression decreases in the Bcl-2 protein and Bcl-2 overexpression blocks CHOP-induced apoptosis [McCullough et al., 2001]. Although several studies have correlated CHOP expression with cell death, the mechanistic link between CHOP and apoptosis remains poorly understood. To address this issue, we define what role, if any, CHOP plays in the regulation of cell death by modulating apoptosis regulating proteins.

In our study, we demonstrated that elevated CHOP expression by introducing a CHOP expression vector or treatment with CHOP inducing agents resulted in a decrease in cFLIP_L expression in renal cancer cells. We also provide evidence that CHOP-induced down-regulation of cFLIP_L is due to activation of the ubiquitin/proteasome pathways.

MATERIALS AND METHODS

CELLS AND MATERIALS

Caki cells, human renal cancer cell, were obtained from the American Type Culture Collection (Rockville, MD). The culture medium used throughout these experiments was Dulbecco's modified Eagle's medium, supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% fetal bovine serum. Lipofectamine2000 was obtained from Life Technologies, Inc. (Rockville, MD). Anti-CHOP and anti-actin antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Anti-cFLIP antibody was purchased from Alexis Corp. (San Diego, CA). Withaferin A (Wit A), Tapsigargin, brefeldin A, Cyclohexamide, MG132 were obtained from Sigma Chemical Co. (St. Louis, MO). Sylibin was purchased from Cayman Chemical (Ann Arbor, MI). Chop siRNA and Grp78 siRNA were obtained from Santa Cruz Biotechnology Inc.

WESTERN BLOTTING

Cellular lysates were prepared by suspending 1×10^6 cells in 100 µl of lysis buffer (137 mM NaCl, 15 mM EGTA, 0.1 mM sodium orthovanadate, 15 mM MgCl₂, 0.1% Triton X-100, 25 mM MOPS, 100 µM phenylmethylsulfonyl fluoride, and 20 µM leupeptin, adjusted to pH 7.2). The cells were disrupted by sonication and extracted at 4°C for 30 min. The proteins were electrotransferred to Immobilon-P membranes (Millipore, Bedford, MA). Specific proteins were detected with an ECL Western blotting kit according to the manufacturer's instructions.

PLASMIDS AND TRANSFECTION

The pcDNA 3.1-CHOP expression construct was kindly provided by Dr. TK Kwon (School of Medicine, Keimyung University, Korea). Briefly, cells were plated onto six-well plates at a density of 5×10^5 cells/well and grown overnight. The cells were transfected with the CHOP expression vector for 5 h using the Lipofectamine2000 method (Invitrogen, Calsbad, CA). After transfection, the cells were cultured in 10% FCS medium for 24 h. Caki/vector and Caki/cFLIP_L overexpressed cells were kindly provided by Dr. TK Kwon.

SMALL INTERFERING RNAs (siRNAs)

The siRNA duplexes used were a pool of three target-specific 19–25 nt siRNAs designed to knockdown CHOP expression (cat no. sc-35437, Santa Cruz Biotechnology). The control siRNA duplex was green fluorescent protein (GFP) with the following sequence: AAG ACC CGC GCC GAG GUG AAG. Cells were transfected with siRNA oligonucleotides using Lipofectamine2000 according to the manufacturer's recommendations.

RNA ISOLATION AND REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (RT-PCR)

Total cellular RNA was extracted from cells using TRIzol reagent (Life Technologies). cDNA was synthesized from 2 µg of total RNA using M-MLV reverse transcriptase (Gibco-BRL, Gaithersburg, MD). The cDNA for c-FLIP_L, CHOP, and actin were amplified by PCR with specific primers. For CHOP, the sense primer was 5'-CAACTGCA-GAGATGGCAGCTGA-3' and the antisense primer was 5'-CTG-ATGCTCCCAATGTTCAT-3' (corresponding to a 536-bp region of CHOP) were used. The sequences of the sense for c-FLIP_L were 5'-CGGACTATAGAGTGCTGATGG-3' and the antisense primer was 5'-GATTATCAGGCAGATTCTAG-3'. PCR products were analyzed by agarose gel electrophoresis and visualized with ethidium bromide.

REAL-TIME RT-PCR

Equal amounts of cDNA were submitted to PCR, in the presence of SYBR green dye with the QuantiTect SYBR Green RT-PCR Kit (Qiagen, Valencia, CA) and the ABI PRISM 6700 Real Time PCR Detection machine (Applied Biosystems, Foster City, CA). The samples quantified using LightCycler Relative Quantification Software version 3.3 (Roche Molecular Systems, Alameda, CA). In each system, the GAPDH housekeeping gene was amplified as a reference standard. cFLIP_L and GAPDH were amplified using primers as follows. For human c-FLIP_L, the following primers were used: 5'-GCTGAAGTCATCCATCAGGT-3' (sense) and 5'-CATACTGAGATG-CAAGAATT-3' (antisense). For human GAPDH: 5'-GTCAACGGA-TTTGGTCTATTG-3' (sense) and 5'-TGGAGGGATCTCGCTCCTGG AAGA. T-3' (antisense). Reactions were prepared in duplicate and heated to 95°C for 10 min followed by 40 cycles of denaturation at 95°C for 10 s, annealing at 55°C for 5 s, and extension at 72°C for 20 s. Standard curves (cycle threshold values vs. template concentration) were prepared for each target gene and for the endogenous reference (GAPDH) in each sample.

IMMUNOPRECIPITATION TO DETECT UBIQUITINATED cFLIP_L

Caki cells were transfected with various plasmid DNAs using the Lipofectamine2000 transfection reagent following the

manufacturer's instructions. After 24 h, the cells were treated with MG132 for 4 h and were then lysed with a buffer containing 1% Triton X-100, 50 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, and protease inhibitor cocktail for 1 h followed by centrifugation. Equal amounts of proteins were immunoprecipitated with anti-FLAG M2 coupled agarose beads (Sigma–Aldrich) for at least 4 h at 4°C. The beads were washed with cell lysis buffer 4 times and then subjected to Western blot to detect ubiquitinated FLIP_L using anti-HA antibody (Abgent; San Diego, CA).

STATISTICAL ANALYSIS

Three or more separate experiments were performed. The statistical analysis was conducted with the paired Student's *t*-test. A *P*-value < 0.05 was considered a significant difference between the experimental and control groups.

RESULTS

CHOP-INDUCING AGENTS DOWN-REGULATED cFLIP_L PROTEIN EXPRESSION

To identify the co-relationship between CHOP and cFLIP_L, we first investigated the effect of the CHOP-inducing drug, Wit A, on cFLIP_L expression in Caki cells. As shown in Figure 1A, Wit A treatment induced CHOP expression in a dose-dependent manner in Caki cells. In contrast, treatments with Wit A dose-dependently down-

regulated cFLIP_L expression. Next, we examined whether other CHOP-inducing drugs such as silybin, thapsigargin (TG), and brefeldin A (BFA) could suppress the cFLIP_L protein expression in Caki cells. Treatment of Caki cells with these CHOP-inducing drugs led to a reduction in cFLIP_L protein levels together with a concomitant increase in the CHOP protein (Fig. 1B–D). These results suggest that CHOP might repress cFLIP_L expression in Caki cells. To prove the major contribution of CHOP in down-regulating cFLIP_L during the unfolded protein responses and linked ER-stress, we analyzed the expression of GRP78 in response to Wit A, silybin, TG, and BFA treatments. However, treatment with silybin, TG, and BFA slightly increased the expression of GRP78 protein, Grp78 protein level was almost constant in Wit A-treated cells (Fig. 1). Next, suppression of Grp78 expression by siRNA transfection failed to inhibit TG- or BFA-induced cFLIP_L down-regulation, showing that GRP78 induction is not required for TG- or BFA-induced cFLIP_L down-regulation (Supplement data #1). These data seem that ER stress is not commonly contributed to CHOP-triggered cFLIP_L down-regulation.

WIT A DOWN-REGULATED cFLIP_L PROTEIN LEVEL

As the cFLIP_L protein was degraded by activated caspases, we examined whether the decreased cFLIP_L protein expression was related to caspase activation. Pre-treatment with z-VAD-fmk, a potent pancaspase inhibitor, failed to recover cFLIP_L protein to the




Fig. 1. CHOP-inducing agents down-regulate cFLIP_L protein expression. Caki cells were treated with several doses of withaferin A (Wit A) (A), thapsigargin (B), silybin (C), and brefeldin A (D) for 24 h. Equal amounts of cell lysates (40 μg) were subjected to electrophoresis and analyzed by Western blot for cFLIP_L, CHOP, Grp78, and actin for normalization. Relative levels of each protein in drug-treated cells were expressed as a ratio of the densitometric value of each protein to that of Actin using the Bio-Rad Gel Doc System.

basal level, indicating that the decreased cFLIP_L protein levels were mediated by caspase-independent pathways (Fig. 2A). To further elucidate the mechanism responsible for the changes in amounts of cFLIP_L protein, we determined cFLIP_L mRNA levels by RT-PCR. cFLIP_L mRNA level remained constant in Caki cells throughout TG treatments at different doses (Fig. 2B), suggesting that TG-mediated degradation of total cFLIP_L protein may be regulated post-transcriptionally. It has been reported that Wit A down-regulated cFLIP_L mRNA expression via inhibiting NF-κB pathways [Lee et al., 2009]. In this study, treatment of Caki cells with Wit A down-regulated cFLIP_L mRNA expression (Fig. 2B). cFLIP_L mRNA level remained also constant in Caki cells throughout BFA, another CHOP-inducing drug, treatments at different doses (Supplement data #2).

CHOP DOWN-REGULATED cFLIP_L EXPRESSION AT THE POST-TRANSCRIPTIONAL LEVEL

We employed Caki cells transiently transfected with CHOP expression vectors or empty vector to determine whether CHOP over-expression could suppress cFLIP_L expression. Ectopic expression of CHOP dose-dependently decreased cFLIP_L protein levels but did not alter cFLIP_L mRNA levels in Caki cells (Fig. 3A,B), suggesting that CHOP down-regulated cFLIP_L expression post-transcriptionally. Next, suppression of CHOP expression by siRNA transfection significantly inhibited Wit A- or TG-induced cFLIP_L down-

regulation, showing that CHOP induction is required for Wit A- or TG-induced cFLIP_L down-regulation (Fig. 3C,D). As shown in Figure 3C,D, basal expression levels of the cFLIP_L protein were higher in CHOP siRNA-transfected cells than those in control siRNA-transfected cells. Taken together, these results suggest that CHOP induction plays a critical role in both Wit A- and TG-induced cFLIP_L down-regulation.

CHOP INCREASED cFLIP_L PROTEIN INSTABILITY AND PROMOTED UBIQUITIN/PROTEASOME-MEDIATED cFLIP_L DEGRADATION

We analyzed cFLIP_L protein stability to further clarify the underlying mechanisms of the decreased cFLIP_L protein level in Wit A- or TG-treated cells. Caki cells were treated with cyclohexamide (CHX) plus Wit A or TG for different time periods. We found that cFLIP_L protein degradation was facilitated by Wit A or TG treatment (Fig. 4A,B), implying that Wit A or TG treatment reduced cFLIP_L protein stability. Based on these results, we hypothesized that the cFLIP_L protein would be degraded by the proteasome-dependent pathway. To confirm this hypothesis, we treated the cells with the proteasome inhibitor MG132. Caki cells were treated with Wit A plus CHX in the absence or presence of MG132 (0.25 μM). As expected, the decreased cFLIP_L protein levels in Wit A- or TG-treated Caki cells almost recovered to basal levels following MG132 treatment (Fig. 5A,B). Immunoprecipitation/Western blotting revealed the highest levels of ubiquitinated FLIP_L




Fig. 2. Withaferin A (Wit A)-induced down-regulation of cFLIP_L is regulated at the post-transcriptional level. A: Caki cells were treated with 1.6 μM withaferin A (Wit A) in the presence or absence of z-VAD (50 μM). Western blotting was performed using anti-cFLIP_L, anti-CHOP, and anti-actin antibodies to serve as control for protein loading. B: Caki cells were treated with the indicated concentrations of Wit A (left panel) or TG (right panel). Total RNA was isolated and RT-PCR analysis was performed. A representative experiment is shown; two additional experiments yielded similar results.




Fig. 3. CHOP down-regulates cFLIP_L protein levels. A and B: CHOP overexpression dose-dependently decreased cFLIP_L protein levels. Caki cells were transfected with CHOP expression vectors at the indicated concentrations for 24 h. After isolating cell lysates or total RNA, RT-PCR, or Western blotting were performed. Relative levels of each protein in drug-treated cells were expressed as a ratio of the densitometric value of each protein to that of actin using the Bio-Rad Gel Doc System. cFLIP_L mRNA expression was detected by real-time RT-PCR (Bottom panel). Data are representative of three experiments. mRNA quantity of each gene was calculated from a standard curve made by amplifying different amounts of GAPDH first-strand cDNA, and normalized by considering the average of independent basal mRNA quantity of non-transfected cells as 1. C and D: CHOP down-regulation by siRNA recovers cFLIP_L protein levels, which were lessened by withaferin A (Wit A) (C) or thapsigargin (D) treatment. Caki cells were transfected with control or CHOP siRNAs and then treated with 1.6 μM Wit A or 0.2 μM thapsigargin. After 24 h, cell extracts were prepared for Western blotting.

in cells transfected with the CHOP expression vector plus MG132 compared with cells transfected with an empty vector plus MG132 or MG132 alone (Fig. 5C), indicating that CHOP increases cFLIP_L ubiquitination. Taken together, we conclude that CHOP facilitated ubiquitin/proteasome-mediated cFLIP_L degradation, leading to cFLIP_L down-regulation in Caki cells.

OVERREGULATION OF cFLIP_L REDUCED CHOP INDUCING AGENT-MEDIATED APOPTOSIS

Next, we examined whether down-regulation of c-FLIP_L by CHOP is critical to stimulate CHOP inducing agent-mediated apoptosis. Overexpression of c-FLIP_L in Caki cells significantly attenuated TG-or-BFA-mediated apoptosis, whereas treatment with TG-or-BFA induced significant apoptosis in Caki/vector cells (Fig. 6A,B). Furthermore, CHOP expression levels by BFA, TG, or silybin

treatment were slightly higher in Caki/vector cells than in Caki/cFLIP_L cells. In addition, cFLIP_L levels were down-regulated by these drugs (Fig. 6C). These data demonstrate that cFLIP_L down-regulation contributed to CHOP-facilitated drug-induced apoptosis.

DISCUSSION

In the present study, we report that treatment with Wit A, TG, BFA, and silybin suppressed cFLIP_L levels. cFLIP_L protein production was suppressed concomitant with CHOP expression. Using a CHOP overexpression system, we demonstrated that elevated CHOP expression resulted in decreased cFLIP_L expression in renal cancer cells. In contrast, siRNA-mediated inhibition of CHOP restored cFLIP_L expression that was prevented by CHOP-inducing agents.




Fig. 4. CHOP increases cFLIP_L instability. A and B: Caki cells were treated with 1.6 μ M withaferin A (Wit A) (A) or 20 μ M thapsigargin (B) in the presence or absence of cyclohexamide (CHX) for the indicated times. Western blotting was performed using anti-cFLIP_L and anti-actin antibodies. Relative levels of each protein in Wit A- or thapsigargin-treated cells were expressed as a fold of the densitometric value of each protein to that of the control.




Fig. 5. CHOP promotes ubiquitin/proteasome-mediated cFLIP_L degradation. A and B: Caki cells were treated with 1.6 μ M withaferin A (Wit A) (A) or 0.2 μ M thapsigargin (B) in the presence or absence of 0.25 μ M MG132 for the indicated times. Western blotting was performed using the anti-cFLIP_L and anti-actin antibodies. Relative levels of each protein in drug-treated cells were expressed as a ratio of the densitometric value of each protein to that of actin using the Bio-Rad Gel Doc System. C: Caki cells were transfected with various plasmids as indicated for 24 h. Then, the cells were treated with 2 μ M MG132 for 4 h. Whole-cell protein lysates were prepared for immunoprecipitation using anti-Flag antibody followed by Western blotting using the anti-HA antibody to detect ubiquitinated FLIP_L and anti-Flag antibody to detect ectopic FLIP_L. NS indicate non-specific band.




Fig. 6. CHOP mediates down-regulation of cFLIP_L contributes to CHOP-stimulated drug-induced apoptosis. A: Caki/vector and Caki/cFLIP_L cells were treated for 24 h with brefeldin A (15 μM), thapsigargin (0.3 μM), or silybin (75 μM). Apoptosis was analyzed as a sub-G1 fraction by flow cytometry. B: Graph of sub-G1 population. Data shown are mean ± SD (n = 3). *P < 0.05 compared to drug-treated pcDNA cells. C: Equal amounts of cell lysates (40 μg) were subjected to electrophoresis and analyzed by Western blot for CHOP, and cFLIP_L.

Finally, we also provided evidence that these events were due to activation of the ubiquitin/proteasome pathways.

Numerous studies have demonstrated that CHOP is induced during the unfolded protein response, which leads to a critical cellular response for the transcriptional control of ER stress-induced apoptosis [Friedman, 1996; Matsumoto et al., 1996; Eymir et al., 1997; Halleck et al., 1997]. Although all reported types of ER stress induce CHOP expression, a mechanistic link between CHOP and apoptosis has remained largely undefined. Several reports have revealed that CHOP acts as transcriptional repressor. For example, CHOP prevented Bcl-2 expression via suppressing bcl-2 transcription by interacting with C/EBP, which mediates their proapoptotic functions [Matsumoto et al., 1996; McCullough et al., 2001]. TG-mediated CHOP induction suppresses PPARγ transcription by sequestering C/EBPβ and limiting the availability of C/EBPβ binding to the PPARγ promoter [Park et al., 2010]. In our study, we found that ectopic expression of c/EBP family such as c/EBPα, c/EBPβ, and c/EBPδ did not affect on cFLIP_L protein expression (Supplement data #6). This result might rule out the possibility that CHOP down-regulated cFLIP_L expression via suppressing cFLIP_L transcription by interacting with C/EBP. It has also been reported that pharmacological induction of CHOP by tunicamycin suppresses p21 expression [Mihailidou et al., 2010]. In contrast, CHOP directly interacts with the DR5 promoter to increase DR5 transcription, which enhances sensitivity to TRAIL [Shiraishi et al., 2005; Yoshida et al., 2005]. Thus, CHOP up-regulates the transcription of proapoptotic factors and down-regulates antiapoptotic genes.

However, it is not well known how CHOP regulates apoptosis regulating proteins at the post-transcriptional level.

A major post-transcriptional mechanism controlling protein levels in eukaryotic cells is ubiquitin-dependent proteasomal turnover. cFLIP expression is strongly regulated at the protein level by altered proteasomal degradation rates [Fukazawa et al., 2001]. In this study, we found that ectopic expression of CHOP dose-dependently led to a decrease in cFLIP_L protein expression but did not alter cFLIP_L mRNA levels in Caki cells, suggesting that CHOP down-regulated cFLIP_L expression post-transcriptionally. Furthermore, we found that CHOP inducing-drugs caused increased cFLIP_L instability and that forced expression of CHOP enhanced levels of ubiquitinated cFLIP_L. JNK activation by tumor necrosis factor (TNF)-α reduces cFLIP_L stability via JNK-mediated phosphorylation and activation of the E3 ubiquitin ligase Itch/AIP4, which promotes cFLIP ubiquitination and degradation through proteasomes [Chang et al., 2006]. It has been reported recently that α-tocopherol ether-linked acetic acid (α-TEA) down-regulation of cFLIP_L protein levels is mediated by the JNK/CHOP/DR5 loop via a JNK-dependent Itch E3 ligase-mediated ubiquitination [Tiwary et al., 2010]. We found that CHOP down-regulated cFLIP_L levels by facilitating ubiquitin/proteasome-mediated cFLIP_L degradation. Our result and that of the previous paper suggested the possibility that CHOP might function as a repressor for cFLIP_L due to cFLIP_L protein depletion by inducing E3 ligase expression, which resulted in activating proteasomal pathway. However, in our system, we failed to detect a role for JNK in mediating CHOP-induced cFLIP_L degradation (data

not shown). In addition, we found that treatment with CHOP inducing-drugs did not affect on Itch expression (Supplement data #5). Thus, Itch is unlikely to be involved in CHOP-mediated cFLIP_L down-regulation in Caki cells. Although, very little information is available concerning the intracellular pathways involved in the effects of CHOP on cFLIP_L expression, further studies are needed to show how CHOP down-regulates cFLIP_L expression by activating the proteasomal pathway or searching for an apoptosis effector molecule that interacts with CHOP.

It has been reported that Wit A down-regulated cFLIP_L mRNA expression via inhibiting NF- κ B pathways [Lee et al., 2009]. In this study, we found that Wit A down-regulated cFLIP_L expression via both suppressing mRNA transcription and increasing cFLIP_L protein instability. Our result and that of the previous paper suggested that Wit A-mediated cFLIP_L down-regulation were caused by suppressing mRNA transcription via inhibiting NF- κ B pathways and increasing cFLIP_L protein instability mediated by CHOP induction. On the other hand, TG or BFA inhibited cFLIP_L protein expression through accelerating protein degradation. Thus, the increasing cFLIP_L protein instability was induced by Wit A, TG, or BFA treatment in our system.

In summary, our results demonstrate that CHOP down-regulated cFLIP_L levels by facilitating ubiquitin/proteasome-mediated cFLIP_L degradation. This was evidenced by the attenuation of Wit A- or TG-mediated cFLIP_L reduction using CHOP siRNA, by increased instability of cFLIP_L, which were detected in cells co-treated with CHX and Wit A or TG by Western blotting, and by increased levels of ubiquitinated cFLIP_L, which were detected in cells treated with MG132 and transfected with CHOP.

For the first time, we demonstrated that CHOP down-regulated cFLIP_L at the protein level, which was mediated by proteasomal degradation. Our findings are significant in that they provide a better understanding of cFLIP_L regulation and provide new insights into CHOP-mediated apoptotic signaling in human cancer cells. Additionally, CHOP-mediated apoptosis will provide a basis for new therapeutic approaches to diseases associated with ER stress.

ACKNOWLEDGMENTS

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Korea Government (MEST) (No. 210-C-000162).

REFERENCES

Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, Liu YC, Karin M. 2006. The E3 ubiquitin ligase itch couples JNK activation to TNF α -induced cell death by inducing c-FLIP(L) turnover. *Cell* 124:601–613.

Eymin B, Dubrez L, Allouche M, Solary E. 1997. Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide. *Cancer Res* 57:686–695.

Fornace AJ, Jr., Alamo I, Jr., Hollander MC. 1988. DNA damage-inducible transcripts in mammalian cells. *Proc Natl Acad Sci USA* 85:8800–8804.

Friedman AD. 1996. GADD153/CHOP, a DNA damage-inducible protein, reduced CAAT/enhancer binding protein activities and increased apoptosis in 32D c13 myeloid cells. *Cancer Res* 56:3250–3256.

Fukazawa T, Fujiwara T, Uno F, Teraishi F, Kadowaki Y, Itoshima T, Takata Y, Kagawa S, Roth JA, Tschopp J, Tanaka N. 2001. Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. *Oncogene* 20:5225–5231.

Goltsev YV, Kovalenko AV, Arnold E, Varfolomeev EE, Brodianskii VM, Wallach D. 1997. CASH, a novel caspase homologue with death effector domains. *J Biol Chem* 272:19641–19644.

Halleck MM, Liu H, North J, Stevens JL. 1997. Reduction of trans-4,5-dihydroxy-1,2-dithiane by cellular oxidoreductases activates gadd153/chop and grp78 transcription and induces cellular tolerance in kidney epithelial cells. *J Biol Chem* 272:21760–21766.

Ichikawa H, Takada Y, Shishodia S, Jayaprakasam B, Nair MG, Aggarwal BB. 2006. Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression. *Mol Cancer Ther* 5:1434–1445.

Irmeler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J. 1997. Inhibition of death receptor signals by cellular FLIP. *Nature* 388:190–195.

Krueger A, Baumann S, Krammer PH, Kirchhoff S. 2001. FLICE-inhibitory proteins: Regulators of death receptor-mediated apoptosis. *Mol Cell Biol* 21:8247–8254.

Lee TJ, Lee JT, Park JW, Kwon TK. 2006. Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation. *Biochem Biophys Res Commun* 351:1024–1030.

Lee TJ, Um HJ, Min do S, Park JW, Choi KS, Kwon TK. 2009. Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. *Free Radic Biol Med* 46:1639–1649.

Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L, Johnston PG. 2006. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. *Oncogene* 25:838–848.

Matta H, Eby MT, Gazdar AF, Chaudhary PM. 2002. Role of MRIT/cFLIP in protection against chemotherapy-induced apoptosis. *Cancer Biol Ther* 1:652–660.

Matsumoto M, Minami M, Takeda K, Sakao Y, Akira S. 1996. Ectopic expression of CHOP (GADD153) induces apoptosis in M1 myeloblastic leukemia cells. *FEBS Lett* 395:143–147.

McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook NJ. 2001. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. *Mol Cell Biol* 21:1249–1259.

Medema JP, Borst J. 1999. T cell signaling: A decision of life and death. *Hum Immunol* 60:403–411.

Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. 2001. NF-kappaB signals induce the expression of c-FLIP. *Mol Cell Biol* 21:5299–5305.

Mihailidou C, Papazian I, Papavassiliou AG, Kiaris H. 2010. CHOP-dependent regulation of p21/waf1 during ER stress. *Cell Physiol Biochem* 25:761–766.

Palacios C, Yerbes R, López-Rivas A. 2006. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. *Cancer Res* 66:8858–8869.

Park SH, Choi HJ, Yang H, Do KH, Kim J, Lee DW, Moon Y. 2010. Endoplasmic reticulum stress-activated C/EBP homologous protein enhances nuclear factor-kappaB signals via repression of peroxisome proliferator-activated receptor gamma. *J Biol Chem* 285:35330–35339.

Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T. 2005. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. *Cancer Res* 65:6364–6370.

- Shu HB, Halpin DR, Goeddel DV. 1997. Casper is a FADD- and caspase-related inducer of apoptosis. *Immunity* 6:751–763.
- Tiwary R, Yu W, Li J, Park SK, Sanders BG, Kline K. 2010. Role of endoplasmic reticulum stress in alpha-TEA mediated TRAIL/DR5 death receptor dependent apoptosis. *PLoS ONE* 5:e11865.
- Wang XZ, Kuroda M, Sok J, Batchvarova N, Kimmel R, Chung P, Zinszner H, Ron D. 1998. Identification of novel stress-induced genes downstream of chop. *EMBO J* 17:3619–3630.
- Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T. 2005. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. *Cancer Res* 65:5662–5667.
- Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA, DeWolf WC, Khosravi-Far R, Olumi AF. 2007. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. *Cancer Res* 67:9425–9434.
- Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT, Remotti H, Stevens JL, Ron D., 1998. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. *Genes Dev* 12:982–995.